Repair of injured tissues is a vital biological method that permits the ordered replacement of dead or damaged cells during an inflammatory response, a mechanism that is crucial for survival. However, tissue damage may occur form many acute or chronic stimuli, including infections, autoimmune reactions, and mechanical injury. The restoration process includes a regenerative phase, in which injured cells are substituted by cells of the same type and there is no lasting indication of damage. Another phase called fibroplasia or fibrosis in which connective tissue changes normal parenchymal tissue.
Tissue Fibrosis is a common cause of morbidity, mortality. The fibrotic process affects nearly every tissue in the body ultimately causes to organ malfunction and death. This disease occurs when the body's natural healing procedure goes twisted; making extra scar tissue that does more damage than good. There are lots of fibrotic diseases, including asthma, cirrhosis, atherosclerosis, scleroderma and pulmonary fibrosis. Pulmonary fibrosis is more common among all these disease in which tissue profound inside the lungs develops stiff, thick, and scarred, reducing the lungs’ capability to expand to take in air, and making it difficult to breathe.
FDA has approved several treatments to avoid fibrotic tissue from forming, doctors typically ponder fibrosis to be a permanent process, and they try to deliberate it as much as possible with anti-inflammatory and immunosuppressive drugs.
Ofev (Nintedanib) and Esbriet (Pirfenidone) are commonly used for the management of Idiopathic Pulmonary Fibrosis.